Beranda › Limfoma Non-Hodgkin › North Carolina › Durham
Uji klinis Limfoma Non-Hodgkin di Durham, NC
16 studi untuk Limfoma Non-Hodgkin mencari peserta di lokasi sekitar Durham (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Menerima pesertaFase 2
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauhnya
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Menerima pesertaFase 1/2
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill · 10 mi jauhnya
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
Menerima pesertaStudi observasional
- Duke University Medical Center - Division of Hematologic Malignancies, Durham
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Menerima pesertaFase 3
- Duke Cancer Institute, Durham
DALY II USA/ MB-CART2019.1 for DLBCL
Menerima pesertaFase 2
- Duke University Medical Center - Division of Hematologic Malignancies, Durham
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Menerima pesertaStudi observasional
- Duke University Medical Center, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi jauhnya
Registry of Older Patients With Cancer
Menerima pesertaStudi observasional
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi jauhnya
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Menerima pesertaFase 1
- University of North Carolina, Chapel Hill · 10 mi jauhnya
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Menerima pesertaFase 1/2
- Duke University Medical Center, Duke Cancer Center, Durham
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Menerima pesertaFase 4
- Duke University Medical Center, Durham
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Menerima pesertaFase 4
- Duke University Medical Center, Durham
Study of SGR-1505 in Mature B-Cell Neoplasms
Menerima pesertaFase 1
- Duke University, Durham
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Menerima pesertaFase 1
- Duke University, Durham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Chapel Hill · 10 mi jauhnya
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Menerima pesertaStudi observasional
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi jauhnya
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Menerima pesertaFase 1
- University of North Carolina, Chapel Hill · 10 mi jauhnya
Uji klinis Limfoma Non-Hodgkin di kota lain
- New York City, NY31 studi
- Houston, TX31 studi
- Boston, MA26 studi
- Nashville, TN21 studi
- Philadelphia, PA20 studi
- Baldwin Park, CA19 studi
- Washington, DC18 studi
- Chicago, IL18 studi
- Atlanta, GA18 studi
- Milwaukee, WI18 studi
- Columbus, OH18 studi
- Dallas, TX17 studi
Studi lain di Durham
- Kanker Payudara64 studi
- Kanker (semua jenis)58 studi
- Kanker Paru Non-Sel Kecil39 studi
- Mieloma Multipel37 studi
- Leukemia Mieloid Akut33 studi
- Kanker Metastatik33 studi
- Kanker Prostat32 studi
- Kanker Paru32 studi
- Kanker Kolorektal28 studi
- Kanker Ovarium27 studi
- Leukemia Limfositik Kronis27 studi
- Gagal Jantung26 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.